Sentences with phrase «with allogeneic transplantation»

Not exact matches

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes with current standard treatment, even for patients who had undergone allogeneic stem cell transplantation.

Collaboration with Hematology and Bone Marrow Transplantation Unit research group in molecular diagnostics applied to the management of patients undergoing allogeneic SCT, especially for the detection of minimal residual disease and early relapse.

In that program, we focused on treating children with both malignant and genetic conditions with generally allogeneic hematopoietic stem cell transplantation.

The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.

These reports suggest that transplantation of MSC could be beneficial in patients with various disorders requiring tissue regeneration, and provide evidence supporting the tolerance of allogeneic MSC by recipients.

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

Bornhäuser M, Kienast J, Trenschel R, et al Reduced - intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open - label randomised phase 3 trial.

Horwitz et al 79 reported that donor MSC contributed to bone remodelling after allogeneic stem cell transplantation (SCT) in 3 children with osteogenesis imperfecta, a rare genetic disorder of type I collagen.

In the future, outpatient blood and bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for allogeneic transplants (transplant from non-twin donor stem cells).

Hutter G and Thiel E Allogeneic transplantation of CCR5 - deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2.

Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor, according to the results of a study published in Lancet Oncology.

We found that, in the allogeneic group, IFN - γ +, IL - 17A +, and IFN - γ / IL -17 A double - positive CD4 + T cells derived from spleen (Fig. 2A, 2B) and MLN (Supplemental Fig. 1A, 1B) increased since the early stage after transplantation compared with the syngeneic group, whereas the IFN - γ — and / or IL - 17A — producing CD8 + T cells increased only at the late stage (Supplemental Fig. 1C, 1D).

Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unrelated donor.

Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.

Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

Macmillan, 2014; Holler, E., et al. «Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft - versus - host disease.»